Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CHMP Knocks Back Teva On Cabazitaxel Hybrid

Executive Summary

Teva has seen its hybrid application for cabazitaxel rejected by the CHMP within the European Medicines Agency, after relying in part on data for docetaxel.

You may also be interested in...



Isatuximab EU Approval Decision Due

Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.

Lupin Expects Exeltis Partnership To Boost Solosec

Lupin is hoping that a newly-struck partnership with women’s health specialist Exeltis will improve the fortunes of its Solosec (secnidazole) bacterial vaginosis and trichomoniasis treatment in the US.

Biogen Sells Samsung Bioepis Stake In $2.3bn Buyout

Biogen has struck a deal that will see it sell its equity stake in the Samsung Bioepis biosimilars joint venture to partner Samsung Biologics for up to $2.3bn.

Topics

Related Companies

UsernamePublicRestriction

Register

GB140298

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel